Characteristic | Amantadine | Placebo | Total | P-value |
---|---|---|---|---|
(N = 16) | (N = 17) | (N = 33) |  | |
Age, mean ± SD, years | 50.69 ± 10.18 | 54.67 ± 9.63 | 52.79 ± 9.94 | 0.154 |
Female, N (%) | 12 (75) | 8 (47.1) | 21 | Â |
> 1 year of college, N (%) | 14 (87.5) | 15 (88.2) | 29 | Â |
Recurrent major depression | 10 (62.5) | 10 (58.8) | 20 | Â |
Bipolar depression, N (%) | ||||
 Bipolar I | 3 (18.75) | 4 (23.5) | 7 |  |
 Bipolar II | 3 (18.75) | 3 (17.6) | 6 |  |
Mean number of depressive episodes per year (past 3 years prior to current episode) | 1.0 ± 1.1 | 1.04 ± 1.2 | 1.02 ± 1.1 | 0.904 |
Mean duration of depressive episodes (weeks) (past 3 years prior to current episode) | 25.6 ± 21 | 23.7 ± 18 | 24.6 ± 19 | 0.781 |
Duration of illness (years) | 12.4 ± 9 | 17.6 ± 11 | 15.1 ± 10 | 0.135 |
Patients with antidepressant or mood stabilizing co-medication, N (%) | 12 (75) | 8 (47.1) | 20 | Â |
Amitriptyline | 3 | 3 | 6 | Â |
Doxepin | 1 | 1 | 2 | Â |
Mirtazapine | 1 | Â | 1 | Â |
Clomipramine | 1 | Â | 1 | Â |
Trimipramine | 1 | Â | 1 | Â |
Tranylcypromine | 1 | Â | 1 | Â |
Moclobemide | 1 | Â | 1 | Â |
Sertraline | Â | 2 | 2 | Â |
Paroxetine | 1 | 1 | 2 | Â |
Dibenzepine | 1 | Â | 1 | Â |
Maprotiline | Â | 1 | 1 | Â |
Lithium | 2 | 2 | 4 | Â |
Carbamazepine | 2 | 2 | 4 | Â |
Valproate | 1 | Â | 1 | Â |
Lorazepam | 3 | 1 | 4 | Â |
Alprazolam | 1 | Â | 1 | Â |
Zolpidem | Â | 1 | 1 | Â |
Sulpirid | 1 | Â | 1 | Â |
L-Thyroxin | Â | 2 | 2 | Â |
Dihydroergotamine | 1 | Â | 1 | Â |
Estrogenes | 1 | 1 | 2 | Â |